TY - JOUR T1 - Obstructive Sleep Apneas and Cardiovascular Diseases. AU - Castiglione,Vincenzo, AU - Morfino,Paolo, AU - Fabiani,Iacopo, AU - Gentile,Francesco, AU - Airò,Edoardo, AU - Volpi,Benedetta, AU - Cardinale,Daniela, AU - Passino,Claudio, AU - Giannoni,Alberto, AU - Emdin,Michele, Y1 - 2026/05/21/ PY - 2026/04/08/received PY - 2026/05/15/revised PY - 2026/05/18/accepted PY - 2026/5/27/medline PY - 2026/5/27/pubmed PY - 2026/5/27/entrez KW - continuous positive airway pressure KW - heart failure KW - obesity KW - obstructive sleep apnea JF - Clocks & sleep JO - Clocks Sleep VL - 8 IS - 2 N2 - Obstructive sleep apnea (OSA) is a sleep-disordered breathing condition characterized by recurrent upper-airway obstruction, leading to intermittent hypoxemia, sleep fragmentation, and sympathetic activation. OSA is highly prevalent in patients with cardiovascular diseases and is strongly associated with hypertension, atrial fibrillation, coronary artery disease, heart failure, and adverse prognosis. This review summarizes current evidence on the pathophysiology of OSA, its cardiovascular consequences, and available diagnostic and therapeutic strategies, with particular attention to clinical implications in cardiology practice. We discuss established treatments such as lifestyle interventions, continuous positive airway pressure, mandibular advancement devices, and selected surgical options, as well as emerging therapies, including pharmacological approaches targeting weight loss and ventilatory control. While OSA treatment improves symptoms and quality of life, evidence for cardiovascular event reduction remains heterogeneous and appears strongly influenced by patient selection and treatment adherence. Identifying patients most likely to benefit from targeted OSA management remains a key challenge. SN - 2624-5175 UR - https://www.unboundmedicine.com/prime/citation/42200975/Obstructive_Sleep_Apneas_and_Cardiovascular_Diseases. DB - PRIME DP - Unbound Medicine ER -